Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegafur-gimeracil-oteracil consolidation therapy for high-risk HER2-negative breast cancer
ChiCTR1800015942Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tegafur in breast cancer (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: 5-year disease-free survival. Started Oct 2018; status: recruiting.
02
Drugs
tegafur
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1800015942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015942.